ABVC BioPharma, Inc. (NASDAQ: ABVC) has closed a private placement of original issue discount senior convertible promissory notes with institutional and other accredited investors, generating gross proceeds of approximately $3.39 million before placement agent fees and offering expenses. The announcement, first reported through NEWMEDIAWIRE, signals a near-term liquidity injection for the clinical-stage biopharmaceutical company as it works to advance a portfolio of drug candidates and an ophthalmic medical device.
The 17.5% OID notes carry an aggregate principal amount of $4,106,060 and mature on June 30, 2027. They become convertible eight months after issuance into common stock at a price equal to 85% of the average of the three volume-weighted average prices for the three trading days immediately prior to conversion, subject to a floor price and adjustments. The discount structure and conversion mechanics mean the deal could result in dilution for existing shareholders, a factor investors typically weigh when assessing small-cap biotech financings.
Proceeds are earmarked for general working capital, funding of subsidiaries, and a $625,000 settlement payment to Lind Global Fund II LP under a definitive release and settlement agreement. That payment is expected to satisfy specified outstanding claims and, according to the company, support its ability to pursue broader financing and business development initiatives. Resolving the Lind Global matter removes a potential overhang and may give ABVC more flexibility in negotiating future capital raises or partnerships.
The offering is also intended to support ABVC's strategy of advancing its pharmaceutical and medical-device portfolio through strategic licensing, subsidiary development, and independent financing. ABVC has set up dedicated platforms across its principal development areas: AiBtl BioPharma Inc. for central nervous system drug programs, OncoX BioPharma for oncology, ForSeeCon Eye for ophthalmic medical-device development and commercialization, and BioKey (Cayman), Inc. for contract pharmaceutical development and manufacturing services as well as an AI biotechnology innovation platform. Through these arrangements, the company seeks to advance development programs while creating opportunities for licensing revenues, milestone payments, future royalties, and equity value.
The company continues to evaluate potential strategic financing and capital-market opportunities for its affiliated businesses as a means to support long-term development and commercialization objectives. For a clinical-stage company with six drug candidates and the Vitargus® device, maintaining separate subsidiary platforms could allow each unit to attract specialized investors or partners without relying solely on the parent company's balance sheet.
WallachBeth Capital, Inc. acted as placement agent, while Hunter Taubman Fischer & Li LLC served as legal counsel to the company and Sichenzia Ross Ference Carmel LLP acted as counsel to the placement agent. The notes and underlying shares have not been registered under the Securities Act of 1933 and may not be offered or sold in the United States absent registration or an applicable exemption. Additional details will be available in the company's Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission. The full release is available at www.newmediawire.com.
